Pharmacological management of GERD: Where does it stand now?

Trends in Pharmacological Sciences

Volumn 32, Issue 4, 2011, Pages 258-264

  Hershcovici, Tiberiu ^a   Fass, Ronnie ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADX 10059; ALGINIC ACID; ANTACID AGENT; AZD 8065; AZID; BACLOFEN; BENATOPRAZOLE; BICARBONATE; CIMETIDINE; CISAPRIDE; DOMPERIDONE; ESOMEPRAZOLE; FAMOTIDINE; GAVISCON; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; LESOGABERAN; METOCLOPRAMIDE; NIZATIDINE; OMEPRAZOLE; PANTOPRAZOLE; PLACEBO; POTASSIUM COMPETITIVE ACID BLOCKER; PROKINETIC AGENT; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; SUCRALFATE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BARRETT ESOPHAGUS; CONFUSION; DIZZINESS; DROWSINESS; DRUG BINDING; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGUS PAIN; EXTRAPYRAMIDAL SYMPTOM; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; LETHARGY; MENTAL HEALTH; NON EROSIVE REFLUX DISEASE; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SOMNOLENCE; STOMACH ACID SECRETION; STOMACH EMPTYING; TACHYPHYLAXIS; UNSPECIFIED SIDE EFFECT; WEAKNESS;

ANIMALS; DRUG DESIGN; ESOPHAGEAL SPHINCTER, LOWER; ESOPHAGUS; GASTRIC ACID; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL AGENTS; HUMANS; MUCOUS MEMBRANE; PROTON PUMP INHIBITORS;

EID: 79954418654     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2011.02.007     Document Type: Review

References (63)

1. J. Dent Epidemiology of gastro-oesophageal reflux disease: a systematic review Gut 54 2005 710 717 (Pubitemid 40559260)
2. G.R. Locke III Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota Gastroenterology 112 1997 1448 1456
3. O.T. Nebel Symptomatic gastroesophageal reflux: incidence and precipitating factors Am. J. Dig. Dis. 21 1976 953 956
4. R.S. Sandler The burden of selected digestive diseases in the United States Gastroenterology 122 2002 1500 1511 (Pubitemid 34465190)
5. R. Weberg, and A. Berstad Symptomatic effect of a low-dose antacid regimen in reflux oesophagitis Scand. J. Gastroenterol. 24 1989 401 406 (Pubitemid 19141424)
6. O. Grove Ranitidine and high-dose antacid in reflux oesophagitis. A randomized, placebo-controlled trial Scand. J. Gastroenterol. 20 1985 457 461 (Pubitemid 15055555)
7. F.C. Hampson Alginate rafts and their characterisation Int. J. Pharm. 294 2005 137 147 (Pubitemid 40462329)
8. B. Simon, and P. Mueller Comparison of the effect of sucralfate and ranitidine in reflux esophagitis Am. J. Med. 83 1987 43 47
9. W. Hameeteman Sucralfate versus cimetidine in reflux esophagitis. A single-blind multicenter study J. Clin. Gastroenterol. 9 1987 390 394 (Pubitemid 17128196)
10. S. Laitinen Sucralfate and alginate/antacid in reflux esophagitis Scand. J. Gastroenterol. 20 1985 229 232 (Pubitemid 15131372)
11. Simon, B. et al. (1996) Sucralfate gel versus placebo in patients with non-erosive gastro-oesophageal reflux disease. Aliment. Pharmacol. Ther. 10, 441-446. (Pubitemid 26174915)
12. J.E. Richter Review article: the management of heartburn in pregnancy Aliment. Pharmacol. Ther. 22 2005 749 757 (Pubitemid 41564353)
13. R. Fass Contemporary medical therapy for gastroesophageal reflux disease Am. Fam. Physician 55 1997 205 212 217-218 (Pubitemid 27034713)
14. M.M. Wolfe, and G. Sachs Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome Gastroenterology 118 2000 S9 S31
15. W.H. Wang Head-to-head comparison of H2-receptor antagonists and proton pump inhibitors in the treatment of erosive esophagitis: a meta-analysis World J. Gastroenterol. 11 2005 4067 4077
16. N.J. Johnson Acute treatment of reflux oesophagitis: a multicentre trial to compare 150 mg ranitidine b.d. with 300 mg ranitidine q.d.s Aliment. Pharmacol. Ther. 3 1989 259 266 (Pubitemid 20113027)
17. P.J. Kahrilas High- versus standard-dose ranitidine for control of heartburn in poorly responsive acid reflux disease: a prospective, controlled trial Am. J. Gastroenterol. 94 1999 92 97 (Pubitemid 29063450)
18. P.L. Peghini Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects Gastroenterology 115 1998 1335 1339 (Pubitemid 28545982)
19. W.K. Fackler Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough Gastroenterology 122 2002 625 632 (Pubitemid 34173813)
20. J. Horn The proton-pump inhibitors: similarities and differences Clin. Ther. 22 2000 266 280 (Pubitemid 30213134)
21. C.W. Howden Appropriate acid suppression in the treatment of acid-related conditions Pharmacol. Ther. 63 1994 123 134 (Pubitemid 24250151)
22. N. Chiba Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis Gastroenterology 112 1997 1798 1810 (Pubitemid 27240763)
23. P. Moayyedi Medical treatments in the short term management of reflux oesophagitis Cochrane Database Syst. Rev. 2007 CD003244
24. B.B. Dean Effectiveness of proton pump inhibitors in nonerosive reflux disease Clin. Gastroenterol. Hepatol. 2 2004 656 664 (Pubitemid 39013424)
25. R. Fass Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease - where next? Aliment. Pharmacol. Ther. 22 2005 79 94 (Pubitemid 41039696)
26. J.M. Moore, and M.F. Vaezi Extraesophageal manifestations of gastroesophageal reflux disease: real or imagined? Curr. Opin. Gastroenterol. 26 2010 389 394
27. R. Fass, and D. Sifrim Management of heartburn not responding to proton pump inhibitors Gut 58 2009 295 309
28. J. Hatlebakk Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily Aliment. Pharmacol. Ther. 12 1998 1235 1240 (Pubitemid 28565964)
29. M. Vakily Pharmacokinetics and pharmacodynamics of a known active PPI with a novel dual delayed release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials Curr. Med. Res. Opin. 25 2009 627 638
30. R. Fass Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease Aliment. Pharmacol. Ther. 29 2009 1261 1272
31. R.H. Hunt Predictable prolonged suppression of gastric acidity with a novel proton pump inhibitor, AGN 201904-Z Aliment. Pharmacol. Ther. 28 2008 187 199 (Pubitemid 351861964)
32. R.H. Hunt Effect on intragastric pH of a PPI with a prolonged plasma half-life: comparison between tenatoprazole and esomeprazole on the duration of acid suppression in healthy male volunteers Am. J. Gastroenterol. 100 2005 1949 1956
33. R.H. Hunt The pharmacodynamics and pharmacokinetics of S-tenatoprazole-Na 30 mg, 60 mg and 90 mg vs. esomeprazole 40 mg in healthy male subjects Aliment. Pharmacol. Ther. 31 2010 648 657
34. G. Morelli Comparison of 24-hour intragastric pH following once-daily treatment with esomeprazole, rabeprazole delayed release and six rabeprazole extended-release formulations Gut 59 2010 A 341
35. L.D.A. Laine Randomised clinical trial: a novel rabeprazole extended release 50 mg formulation vs. esomeprazole 40 mg in healing of moderate-to-severe erosive oesophagitis - the results of two double-blind studies Aliment. Pharmacol. Ther. 33 2011 203 212
36. C.W. Howden Review article: immediate-release proton-pump inhibitor therapy - potential advantages Aliment. Pharmacol. Ther. 22 Suppl. 3 2005 25 30 (Pubitemid 41783984)
37. P.O. Katz Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms Aliment. Pharmacol. Ther. 25 2007 197 205 (Pubitemid 46046376)
38. Y. Chowers PPI activity is optimized by VB101, a parietal cell activator Gastroenterology 134 2008 A-172
39. Y.X. Yang Long-term proton pump inhibitor therapy and risk of hip fracture J. Am. Med. Assoc. 296 2006 2947 2953
40. R.J. Laheij Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs J. Am. Med. Assoc. 292 2004 1955 1960 (Pubitemid 39411203)
41. S. Dial Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies Can. Med. Assoc. J. 171 2004 33 38 (Pubitemid 38925116)
42. Y.X. Yang, and D.C. Metz Safety of proton pump inhibitor exposure Gastroenterology 139 2010 1115 1127
43. K.E. McColl Effect of proton pump inhibitors on vitamins and iron Am. J. Gastroenterol. 104 Suppl. 2 2009 S5 S9
44. L. Laine, and C. Hennekens Proton pump inhibitor and clopidogrel interaction: fact or fiction? Am. J. Gastroenterol. 105 2010 34 41
45. D.L. Bhatt Clopidogrel with or without omeprazole in coronary artery disease N. Engl. J. Med. 363 2010 1909 1917
46. P.J. Kahrilas A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis Clin. Gastroenterol. Hepatol. 5 2007 1385 1391 (Pubitemid 350181597)
47. B receptors in the brain-gastroesophageal axis Am. J. Physiol. Gastrointest. Liver Physiol. 281 2001 G311 G315
48. B agonist baclofen in patients with gastro-oesophageal reflux disease Gut 50 2002 19 24 (Pubitemid 34028297)
49. B agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors Gut 52 2003 1397 1402 (Pubitemid 37176716)
50. M.F. Vela Baclofen decreases acid and non-acid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH Aliment. Pharmacol. Ther. 17 2003 243 251 (Pubitemid 36174255)
51. R. Lal Arbaclofen placarbil, a novel R-baclofen prodrug: improved absorption, distribution, metabolism, and elimination properties compared with R-baclofen J. Pharmacol. Exp. Ther. 330 2009 911 921
52. L.B. Gerson Arbaclofen placarbil decreases postprandial reflux in patients with gastroesophageal reflux disease Am. J. Gastroenterol. 105 2009 1266 1275
53. G.E. Boeckxstaens Effects of lesogaberan on reflux and lower esophageal sphincter function in patients with gastroesophageal reflux disease Gastroenterology 139 2010 409 417
54. G.E. Boeckxstaens Efficacy and tolerability of the novel reflux inhibitor, AZD3355, as add-on treatment in GERD patients with symptoms despite proton pump inhibitor therapy Gastroenterology 136 2009 A436
55. C. Keywood A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and symptoms in gastro-oesophageal reflux disease Gut 58 2009 1192 1199
56. M. Handa Antidepressant treatment of patients with diffuse esophageal spasm: a psychosomatic approach J. Clin. Gastroenterol. 28 1999 228 232 (Pubitemid 29141102)
57. P.J. Kahrilas American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease Gastroenterology 135 2008 1383-1391.e5
58. E. Masci Comparison of ranitidine, domperidone maleate and ranitidine + domperidone maleate in the short-term treatment of reflux oesophagitis Drugs Exp. Clin. Res. 11 1985 687 692 (Pubitemid 16203083)
59. M. Ruth The effect of mosapride, a novel prokinetic, on acid reflux variables in patients with gastro-oesophageal reflux disease Aliment. Pharmacol. Ther. 12 1998 35 40 (Pubitemid 28057402)
60. K. Madan Comparison of efficacy of pantoprazole alone versus pantoprazole plus mosapride in therapy of gastroesophageal reflux disease: a randomized trial Dis. Esophagus 17 2004 274 278 (Pubitemid 40123800)
61. H. Miwa Randomised clinical trial: efficacy of the addition of a prokinetic, mosapride citrate, to omeprazole in the treatment of patients with non-erosive reflux disease - a double-blind, placebo-controlled study Aliment. Pharmacol. Ther. 33 2011 323 333
62. S. Futagami The prokinetic effect of mosapride citrate combined with omeprazole therapy improves clinical symptoms and gastric emptying in PPI-resistant NERD patients with delayed gastric emptying J. Gastroenterol. 45 2010 413 421
63. Y.S. Kim Effect of itopride, a new prokinetic, in patients with mild GERD: a pilot study World J. Gastroenterol. 11 2005 4210 4214 (Pubitemid 41086873)